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biomédecine vétérinaire, Faculté de médecine
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Bioavailability and pharmacological effects of tiludronate were compared when
administered as an intravenous (i.v.) bolus at a dosage of 0.1 mg ⁄kg body
weight (b.w.) once daily for 10 consecutive days (group 1, n = 6) and as a
single constant rate infusion (CRI) at a total dose of 1 mg ⁄ kg b.w. (group 2,
n = 6) in healthy adult horses.
Tiludronate and carboxy-terminal cross-linking telopeptide of type I collagen
(CTX-1) were measured in plasma and urine.
There was no statistically significant difference in area under the curve (AUC)
and clearance (Cl) between the two groups. Bioavailability of the CRI was 103%
(not significantly different) that of the 10 daily i.v. bolus doses. Cumulative
urine tiludronate excretion could not be compared between groups because of
poor sensitivity of the assay in urine. Plasma and urine CTX-1 levels were not
different between groups throughout the study. However, interindividual
variations were greater in group 1 than in group 2. A significant decrease in
CTX-1 levels was observed in plasma after the first administration in group 1,
but not in urine; while in group 2, a significant decrease in CTX-1
concentrations was observed after treatment in both plasma and urine.
In conclusion, both dosage regimens of tiludronate produced similar plasma
exposure and pharmacological effects in adult healthy horses.
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INTRODUCTION
Tiludronate, a non-nitrogen-containing bisphosphonate, inhibits
osteoclast-mediated bone resorption by interfering with intracel-
lular pathways required for normal cell function and survival
(Rogers et al., 1999). In particular, it has been shown that
tiludronate is metabolically incorporated into cytotoxic, nonhy-
drolysable analogues of ATP, accumulating intracellularly and
leading to osteoclast apoptosis (Rogers et al., 1999; Rogers,
2003). It has also been shown to disrupt the cytoskeleton
(Murakami et al., 1997) and to inhibit the activity of the proton
pump (David et al., 1996) of resorbing osteoclasts. Bisphospho-
nates are widely used in human medicine in the treatment of
different bone pathologies. Tiludronate is particularly indicated
in the treatment of Paget’s disease (Peris et al., 2002, 2006;
Alexandersen et al., 2005), while more potent nitrogen-contain-
ing bisphosphonates, such as alendronate, zoledronate or
ibandronate, are preferred in the treatment of postmenopausal
osteoporosis, bone metastases and the hypercalcemia of malig-
nancy (Bobba et al., 2006; Guay, 2006).
In horses, tiludronate presents a strong affinity for calcified
tissues including bone, leading to a rapid distribution from
plasma and an accumulation into deep compartments. It is not
metabolized and is excreted by glomerular filtration (CEVA Santé
Animale, unpublished data). These are pharmacokinetic (PK)
characteristics shared by all bisphosphonates in other species
including humans (Fleisch, 1997; Davi et al., 1999; Cremers
et al., 2005; Lasseter et al., 2005). Bisphosphonates can persist
in bone for several years after administration by forming
complexes with hydroxyapatite crystals, until being finally
absorbed by active osteoclasts where they exert their inhibitory
action (Lasseter et al., 2005). In humans, the half-lives of the
bisphosphonates are reported to be around a few days with
values ranging from 2 h to 11 days depending on molecule,
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method and study design (Barrett et al., 2004; Lasseter et al.,
2005; Yun et al., 2006), while bone half-lives are reported to be
around 11 years (Lasseter et al., 2005).
The pharmacodynamic (PD) effects of bisphosphonates in
humans have most commonly been estimated using the
osteoporotic fracture risk reduction, the bone mineral density
(BMD) assessment at different zones of interest (Reid, 2006) and
by the measurement of biomarkers of bone metabolism in plasma
or urine (Ravn et al., 2002; Cremers et al., 2005; Reginster et al.,
2005). In horses, several blood biomarkers of bone metabolism
have been tested successfully, including the carboxy-terminal
cross-linking telopeptide of type I collagen (CTX-1) as a marker of
bone resorption (Kellerhouse et al., 2000; Delguste et al., 2007).
In human medicine, CTX-1 is commonly assessed in both plasma
and urine, as it is considered as one of the most relevant markers
in the monitoring of a bisphosphonate treatment (Reginster
et al., 2005; Peris et al., 2006).
Tiludronate is licensed in Europe for the treatment of
degenerative joint disease of the tarsus (bone spavin) and
navicular disease in horses, at a dosage of 0.1 mg ⁄ kg body
weight (b.w.) by intravenous (i.v.) bolus once daily for 10
consecutive days. Efficacy of this dosage has been confirmed by
a clinical study in horses suffering from navicular disease
(Denoix et al., 2003). Previous studies have evaluated the
safety (Varela et al., 2002) and efficacy (Coudry et al., 2007;
Delguste et al., 2007) of a single dose of 1 mg ⁄ kg b.w. by slow
i.v. infusion. As the latter protocol may be considered a more
practical dosage regimen by some, this study was performed to




A unicentric parallel design study was conducted using two
groups of six horses. Twelve healthy 3- to 5-year-old Standard-
bred horses were selected for this study, among which six were
mares and six were geldings.
To be included in the study, horses had to: (1) be normal on
physical examination, (2) have a lameness score £ 2 on a scale
of 5 (Stashak, 1998), (3) have values of serum urea and
creatinine concentrations within the reference range (as an
indirect assessment of kidney function) and (4) have no history
of previous treatment with tiludronate or corticosteroids.
For the lameness examination, horses were observed while
walking in a straight line and in small circles in both directions,
then while trotting in a straight line. If the gait was considered
abnormal, flexion tests followed by movement were performed
on the suspected limb in order to confirm the suspicion of
lameness. If lameness was observed in several limbs, the
lameness score was based on the most severely affected limb.
Blood samples for measuring serum urea and creatinine
concentrations were obtained by venipuncture of the right
jugular vein. Blood sample was collected in sterile 5 mL
Vacutainer glass tubes with no additives, and immediately
submitted for analysis by colorimetry.
The horses were randomly assigned to a treatment group
according to gender, so that each group consisted of three mares
and three geldings. Horses of group 1 (aged 3.5 ± 0.8 years,
weighing 441 ± 28 kg, mean ± SD) were administered tiludro-
nate as an i.v. bolus of 0.1 mg ⁄ kg b.w. once daily for 10
consecutive days. Horses of group 2 (aged 3.0 ± 0.0 years,
weighing 471 ± 66 kg) were administered tiludronate as a
single constant rate infusion (CRI) at a total dose of 1 mg ⁄ kg
b.w.
To reduce the possible influence of estrus cycle on the
concentrations of CTX-1 in blood and urine, all mares under-
went ultrasonographic examination of the reproductive tract 7–
10 days before treatment administration. Mares found to be in
diestrus were administered an injection of cloprostenol (Estru-
mate; Schering Plough, Kenilworth, NJ, USA) to induce
luteolysis such that all mares were in the same phase of the
estrus cycle at the time of treatment administration.
Tiludronate administration
Two products were tested: the commercial formulation of
tiludronate (Tildren; CEVA Santé Animale, Libourne, France)
(10 vials each containing 50 mg tiludronate) and a nonmar-
keted formulation containing 500 mg tiludronate per vial. Both
products were presented as lyophilized powder extemporane-
ously reconstituted with saline (Baxter, Lessines, Belgium) as a
0.5% (group 1) or 2% (group 2) injectable solution of
tiludronate. The volume of reconstituted solution to be admin-
istered to each horse was calculated on the basis of b.w., and
rounded to the nearest 0.5 mL. Horses of group 1 received 10
daily bolus i.v. administrations of 0.1 mg ⁄ kg b.w. (0.0991 ±
0.0018 mg ⁄ kg b.w.) of tiludronate from day 0 to day 9 in the left
jugular vein. Horses of group 2 received a single CRI of a total
dose of 1 mg ⁄ kg b.w. (0.998 ± 0.006 mg ⁄ kg b.w.) at an
estimated rate of 25 mL ⁄ min of tiludronate on day 0 as a 1-L
i.v. infusion in the left jugular vein. To obtain one litre of final
solution for each horse in group 2, independently of the horse’s
b.w., a volume of saline (Baxter) equivalent to the volume of
reconstituted 2% solution necessary to treat the horse was
removed from a 1L bag (Baxter) before adding the reconstituted
solution. All treatments were administered between 8 AM and
12 PM. Any abnormal behaviour of the horses during or
immediately after the administration of treatments was recorded.
Tiludronate assay
Blood samples for tiludronate assay were collected from the right
jugular vein, into sterile Vacutainer glass tubes with heparin
following the schedule presented in Table 1.
Plasma was separated by centrifugation (1500 g at room
temperature for 15 min) and stored at )20 C within 1 h of
collection until analysis.
Urine collection for tiludronate assay was performed using
plastic bags tied to specially designed gender-specific harnesses
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(HFL, Newmarket, England), following the schedule presented in
Table 1.
After each micturition, the time and horse number were
recorded, and bags were removed for sampling while empty bags
were tied to the harness. Two sets of individual bags were
labelled with the horse’s number to avoid cross-contamination,
and were alternately used until damaged in order to ‘wash’ the
deposits of the previous micturitions, and so to minimize the
possible losses because of these deposits.
For sampling, urine bags were gently shaken to avoid large
deposits on the bottom before being poured into a graded, 2-L
cylinder for careful volume measurement of the total micturition
(rounded to the nearest 20 mL). Urine was then magnetically
mixed using a magnetic stirring rod while a representative
sample equivalent to 1 ⁄ 100 of the total volume of the
micturition was sampled and stored at 4 C within 1 h of
collection until pooling. Urine samples were pooled by 4-h
periods on day 0, and by 24-h periods on subsequent days.
To represent better the accumulation of drug in urine during
a given period, samples obtained from a micturition occurring
within the first 30 min of a collection period were pooled with
the samples from the previous period. The actual volume of the
pool was evaluated carefully in a 50- or 250-mL cylinder,
rounded to the nearest 0.5 mL and recorded for comparison with
the calculated expected volume. Urine was then homogenized
again by magnetic shaking during collection of the final samples,
which were stored at )20 C within 28 h of collection of the first
sample of the pool until analysis.
Both plasma and urinary concentrations of tiludronate were
measured by high performance liquid chromatography (HPLC)
with UV detection. The method was validated in terms of
precision, accuracy and recovery. The limit of quantification
(LOQ) was 0.025 and 0.05 mg ⁄ L, and the limit of detection was
0.011 and 0.0 mg ⁄ L, in plasma and urine respectively. Intraday
coefficients of variation ranged from )0.8% to 6.9% and from
)3.2% to 5.19% in plasma and urine, respectively. Interday
coefficients of variation ranged from 1.87% to 5.36% and from
)3.6% to 4.88% in plasma and urine, respectively. Plasma
concentrations vs. time curves were plotted for PK analysis.
The urine concentrations were multiplied by the total volume
of urine collected during the collection period corresponding to
the pool in order to obtain the total amount of tiludronate
excreted by collection period. These amounts were then added to
obtain the total amount of tiludronate excreted by each horse
and a cumulative urine excretion vs. time curve was plotted, for
comparison between treatment groups.
CTX-1 assay
Blood and urine samples for CTX-1 assay were collected before
treatment on days )5, )3, and )1 in both groups; during
treatment on days 1 and 5 in group 1 only; and 1, 3, 6, 10, 20,
30 and 60 days after treatment completion in both groups (i.e.
on days 10, 12, 15, 19, 29, 39 and 69 in group 1, and on days
1, 3, 6, 10, 20, 30 and 60 in group 2). After an overnight fast,
blood samples were collected between 8.00 AM and 10.00 AM by
venipuncture of the right jugular vein into sterile Vacutainer
glass tubes with ethylene diamine tetraacetic acid (EDTA), and
urine samples were collected from the micturition the closest to
10.00 AM. In blood and urine, respectively plasma and super-
natant were separated by centrifugation (1500 g at room
temperature) and stored at )20 C within 1 h after collection
until analysis. Quantification of CTX-1 concentration was
performed in both plasma and urine by an automated immu-
noenzymatic assay previously validated in horses (Crosslaps
Elecsys; Roche Diagnostics, Basel, Switzerland) (Carstanjen et al.,
2004).
PK analysis
Pharmacokinetic analyses were performed using KINETICA version
4.4.1 software (Thermo electron, Mountain View, CA, USA).
Table 1. Plasma and urine sampling schedule for the tiludronate assay in 12 Standardbred horses
Group 1 (n = 6): 10 daily administrations of 0.1 mg ⁄ kg b.w.
tiludronate as i.v. bolus
Group 2 (n = 6): single administration of 1 mg ⁄ kg b.w.
tiludronate as slow infusion
Pretreatment Plasma: just before bolus 1 Plasma: just before start of infusion
Urine: single sample on day )1 Urine: single sample on day )1
During treatment Plasma:
5, 10, 15, 30 min and 1, 2, 4, 8, 12 and 24 h* after bolus 1
8 and 24 h* after bolus 2–9
Plasma:
5, 10, 15 and 30 min after start of infusion
End of infusion (time recorded)
Urine: continuous collection starting immediately after
bolus 1
Urine: continuous collection starting with infusion
Post-treatment Plasma:
5, 10, 15, 30 min and 1, 2, 4, 8, 12, 24, 48, 72, 96 and
168 h after bolus 10
Plasma:
1, 2, 4, 8, 12, 24, 48, 72, 96 and 168 h after start of
infusion
Urine:
Continuous collection until 168 h after bolus 10
Over 24-h periods, respectively, 10, 20, 30, 40, 50 and
60 days after bolus 10 (i.e. on days 19, 29, 39, 49, 59 and
69)
Urine:
Continuous collection until 168 h after start of infusion
Over 24-h periods, respectively, 10, 20, 30, 40, 50 and
60 days after infusion (i.e. on days 10, 20, 30, 40, 50
and 60)
*Blood samples taken at 24 h after bolus injections 1–9 were taken immediately before the next bolus administration.
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For both groups, a noncompartmental approach was used to
estimate PK parameters.
Assuming that clearance (Cl) remained unchanged between
the two dosing regimens, and that steady-state was achieved by
day 10 for group 1, relative plasma bioavailability (Fp) was
assessed using group 1 (currently approved dosage rate) as
reference. Hence, the total plasma exposure between zero to
infinity for group 2, represented by the total area under the
curve (AUCtot), was compared with the area under the curve at
steady-state (AUCss) corresponding to the total plasma exposure
from 0 to 24 h measured at the last dose for group 1, multiplied
by the dose ratio (Rowland & Tozer, 1995).
Urinary tiludronate excretion parameters were also to be used
to determine relative bioavailability. These were to be obtained
from a cumulative urine excretion vs. time curve. Relative urine
bioavailability (Fu) is determined by the ratio of total amount of
drug excreted in urine to last sampling (Xutot) (Rowland & Tozer,
1995).
PD analysis
The PD effects of tiludronate were assessed by measurement of
plasma and urine CTX-1 concentrations. The results were
expressed as percentages of baseline value for each horse.
Baseline values were calculated as the median of the three values
from days )5 to )1.
Statistical analysis
Statistical analysis was run on SAS software, version 8.2 (SAS
Institute Inc., Cary, NC, USA).
After normalization of the data, a linear mixed model was used
to describe the experiment, as follows:
Ygijk ¼ ıþ Gi þ Sj þ ðGSÞij þ DðGSÞijk þ aijl þ eijkl
where Y is the CTX-1 measurement, ı̀ is the grand mean, Gi, Sj
and Dk are the main effects of group, gender and date respec-
tively, and (GS)ij are the group–gender interaction effects. Lower
case letters represent group number (i), gender (j), date of
measurement (k) and animal number (l). The aijl represent the
random effects of animals while eijkl are the random errors
associated with the measurements. Standard stochastic
assumptions are made that the random effects aijl and eijkl are
normally distributed with zero means and variances ra
2 and re
2
respectively. The aijl were assumed to be independent but fluc-
tuations were detected in the variances over time so the
covariance structure was modelled with a first-order auto-
regressive structure (PROC MIXED, Type = AR(1); SAS Institute
Inc., 1999) for which the co-variances between repeated mea-
sures on the same animal decrease exponentially with time. Fi-
nally, least-squares means were obtained for the main and
interaction effects along with all pair-wise comparisons.
For the other variables (AUC, Cl and Xutot), the model
included only the fixed effects Gi, Sj and (GS)ij; the residuals were
assumed independent and identically normally distributed with
zero mean and common variance.
The significance threshold was set at 5% (P-value <0.05).
The protocol was approved by the Animal Care Committee of
the University of Liege, which abides by the requirements of the
directive 86 ⁄ 609 of the European Community Council. Exper-
iments followed guidelines equivalent to those in ‘Guide to the
care and use of experimental animals’ published by the
Laboratory Animal Resources Commission on Life Sciences
National Research Council (National Academy press, Washing-
ton, DC, 1996).
The study also complied with the International Cooperation
and Harmonization of Technical Requirements for Registration
of Veterinary Medicinal Products entitled Guideline 9 Good
Clinical Practice for the animal phase. The analytical phases for
tiludronate and CTX-1 determinations were performed in
accordance with the Directive 2004 ⁄ 10 ⁄ EC of the European
Parliament and the Council of 11 February 2004 and ‘Arrêté du
28 Janvier 2005 relatif aux Bonnes Pratiques de Laboratoire
pour les médicaments vétérinaires: JO du 20 ⁄ 02 ⁄ 2005’.
RESULTS
Horse 11 (group 2) showed slight signs of restlessness (kicking)
during the infusion, which could possibly be because of
abdominal discomfort. No further clinical signs were observed
after the end of infusion in this horse. None of the other horses
showed adverse effects during or after treatment in either group.
The rate of infusion in group 2 was 25.77 ± 2.86 lg ⁄ kg ⁄ min.
Individual mean daily outputs of urine ranged from 5.32 to
12.34 L ⁄ day (10.98–27.07 mL ⁄ kg ⁄ day) with a median value of
6.95 L ⁄ day (16.16 mL ⁄ kg ⁄ day). Urine daily output was similar
in group 1 (range 5.32–12.34, median 6.26 L ⁄ day) and group 2
(range 5.69–10.51, median 7.71 L ⁄ day).
PK analysis
Plasma concentrations of tiludronate vs. time curves
(mean ± SD) for groups 1 and 2 are shown in Figs 1 & 2,
respectively.
The main PK parameters of interest derived from the
noncompartmental analysis are given in Tables 2 and 3. After
determining that the extrapolated portion of the AUC repre-
sented no more than 10% of the total estimated AUC, it was
determined that the AUCtot could be used for group 2.
There was no significant difference (P = 0.743) between the
AUC corrected for dosage for group 1 (AUCss) and group 2
(AUCtot). There was no significant difference between groups for
Cl (P = 0.564). There were no significant differences between
males and females for AUC (P = 0.509) and Cl (P = 0.583).
As Cl was not statistically different between groups, the
aforementioned formula could be adequately used to calculate
Fp, using the mean AUC for each group only. This was
103.1%.
Several horses in both groups had tiludronate urine concen-
trations below LOQ at different postadministration time intervals,
especially in group 1 (data not shown). Tiludronate concentra-
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Fig. 1. Mean (±SD) log plasma tiludronate
concentration vs. time in Standardbred horses
after daily intravenous administration as
bolus of 0.1 mg tiludronate ⁄ kg once daily for
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Fig. 2. Mean (±SD) log plasma tiludronate
concentration vs. time in Standardbred horses
after a single CRI of tiludronate of
25.77 ± 2.86 lg ⁄ kg ⁄ min and a total dose of
1 mg ⁄ kg (group 2, n = 6).
Table 2. Steady-state pharmacokinetic parameters of tiludronate in plasma following daily intravenous injections (as bolus) of 0.1 mg ⁄ kg b.w. of
tiludronate for 10 consecutive days to six Standardbred horses (group 1)
Horse AUCss (mgÆh ⁄ L) AUMCss (mgÆh ⁄ L) Clss (L ⁄ h ⁄ kg) Cmin,ss (mg ⁄ L) Cmax,ss (mg ⁄ L) Cave (mg ⁄ L) R
1 3.62 23.54 0.027 0.047 1.198 0.151 1.26
2 4.02 31.56 0.025 0.065 1.03 0.168 1.31
3 3.62 27.17 0.027 0.058 0.955 0.151 1.46
4 3.25 21.87 0.030 0.053 1.154 0.135 1.48
5 3.05 20.06 0.032 0.052 1.204 0.127 1.47
6 5.01 34.47 0.020 0.07 1.5 0.209 1.19
N 6 6 6 6 6 6 6
Mean 3.76 26.44 0.027 0.058 1.174 0.157 1.36
SD 0.698 5.679 0.0042 0.0086 0.1881 0.0291 0.124
Cave, average concentration.
Table 3. Pharmacokinetic parameters of tiludronate in plasma following one intravenous injection (as CRI) of a total dose of 1 mg ⁄ kg b.w. of
tiludronate to six Standardbred horses (group 2)
Horse AUCtot (mgÆh ⁄ L) Ke (h)1) Elimination half-life (h) MRT (h) Clearance (L ⁄ h ⁄ kg) Vd (L ⁄ kg)
7 38.15 0.018 37.57 18.17 0.026 1.41
8 37.56 0.011 65.24 37.48 0.027 2.50
9 40.66 0.012 58.05 33.77 0.025 2.07
10 34.72 0.015 47.17 25.89 0.029 1.94
11 37.77 0.016 42.82 22.84 0.026 1.63
12 45.56 0.012 57.62 32.931 0.022 1.84
N 6 6 6 6 6 6
Mean 39.07 0.014 51.41 28.51 0.026 1.90
SD 3.70 0.003 10.56 7.40 0.0022 0.376
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tions were also below LOQ in all subjects in both groups by
20 days after the last administration. The total amount of
tiludronate excreted in urine was significantly lower in group 1
than in group 2 (P = 0.0003), but no significant gender effect
was observed for this parameter (P = 0.110). Because of the
large number of missing data (concentrations below LOQ) for
several time-points in both groups of horses, PK analyses could
not be performed on urine tiludronate excretion data, and the
relative bioavailability could not be determined.
PD analysis
Plasma CTX-1 concentrations (expressed as percentage of
baseline value) vs. time curves of groups 1 and 2 are shown in
Figs 3 & 4, respectively. Baseline is the median of the three
pretreatment values, and is by definition 100%. Horse 6 (mare
from group 1) had multiple inexplicable plasma concentrations,
and was excluded from the analysis for CTX-1 in both plasma
and urine.
In plasma, a significant decline in plasma CTX-1 concentra-
tions was seen between day 0 and day 1 in both groups
(P = 0.047 and 0.005 in groups 1 and 2, respectively). This
difference was still significant on day 3 in group 2 (P = 0.036).
There were no significant differences in the evolution of plasma
(P = 0.488) or urine (P = 0.827) CTX-1 concentrations be-
tween groups.
A significant transient decrease in urinary CTX-1 was seen
between day 0 and day 1 in group 2 (P = 0.028), but not in
group 1 (P = 0.219) (data not shown).
No gender effect was seen on CTX-1, in plasma (P = 0.973) or
in urine (P = 0.525).
DISCUSSION
This study established that plasma exposure to tiludronate was
similar after administered by two different dosage regimens with
a same cumulative dose of 1 mg ⁄ kg. Moreover, no differences
between groups were evidenced in the overall evolution of the
bone resorption marker CTX-1. This suggests that the adminis-
tration of 10 daily boluses could be practically replaced by a
single CRI.
The bioequivalence is based on the assumption that a similar
plasma exposure to a drug gives rise to a similar effect (Toutain &
Koritz, 1997). Hence, bioequivalence implies similar bioavaila-
bilities of two drug formulations. Nevertheless, plasma concen-
tration profiles have to be compared after administration of the
two products by the same route and at the same dose.
For comparison of the same product given by the same route
at the same total dose, but administered as single or divided
doses, the guidelines have to be adapted. In this study, standard
parameters for the assessment of bioequivalence, such as
maximal plasma concentration and time for maximal plasma
concentration were not considered relevant for the comparison
of the same cumulative dose of the drug given as a CRI or as 10
daily bolus injections. Therefore, this study focused on compar-
ing plasma exposure to the drug (i.e. determination of relative























Fig. 3. Median and range of plasma CTX-1
concentrations (expressed as percentage of
baseline value) vs. time in Standardbred
horses after daily intravenous administration
of tiludronate as boluses of 0.1 mg ⁄ kg once
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Fig. 4. Median and range of plasma CTX-1
concentrations (expressed as percentage of
baseline value) vs. time in Standardbred
horses after a single CRI of tiludronate of
25.77 ± 2.86 lg ⁄ kg ⁄ min and a total dose of
1 mg ⁄ kg (group 2, n = 6).
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prohibited the use of a cross-over designed study. Constancy of Cl
is the only requirement for relative bioavailability calculation
(Rowland & Tozer, 1995). As tiludronate exerts its inhibitory
action after endocytosis by active osteoclasts from bone under-
going resorption (Rogers et al., 1999), it is likely that bone
concentrations of tiludronate would be a better predictor of
clinical effect than plasma concentrations (Cremers et al., 2005).
However, invasive methods are required to assess bone concen-
trations. Moreover, bone concentrations are not homogeneous
between and within bones (Davi et al., 1999). Therefore,
pharmacological effects of bisphosphonates are thought to be
site-dependent as they depend on both local drug concentration
and local resorption activity for drug endocytosis (Sato et al.,
1991). The total amount of tiludronate stored in bones could
nevertheless reflect the total effect. As tiludronate is not
metabolized and excreted almost exclusively in urine (CEVA,
unpublished data), it was suggested that calculation of plasma
exposure along with cumulative urine excretion would permit to
assess the total amount of tiludronate stored in bones. The
comparison of relative bioavailability from both plasma and
urine could have permitted indirect comparison of bone exposure
between dosage regimens. In turn, bone exposure could be
related to CTX-1. Unfortunately, the lack of sensitivity of
the tiludronate assay did not allow accurate measurement of
tiludronate concentrations in urine. The comparison of PK
between groups was therefore limited to plasma exposures.
These were compared after confirming that Cl was
dose-independent.
In the bolus group (group 1), it was assumed that steady-state
had been reached by the 10th dose. This assumption was
supported by the visual inspection of the mean concentration vs.
time plots at 8 and 24 h after each administration, which
showed a plateau from the 7th administration. Moreover, the
accumulation factor was limited (1.36 ± 0.124, range 1.19–
1.48), suggesting that the dosage interval (i.e. 24 h) was inferior
to but relatively close to the plasma half-life of tiludronate. This,
in turn, suggested that a 10-day course of daily administrations
was sufficient to consider that steady-state had been reached, as
90% of the plateau is reached after 3.3 half-lives and 99% after
seven half-lives in multi-doses regimens. Relative plasma bio-
availability was therefore determined using AUCtot for the
infusion group (group 2) and AUCss for the bolus group,
multiplied by the dose ratio. A result close to 100% was expected
to confirm that the two dosage regimens produced a comparable
plasma exposure, as stated by the statistical analysis. With a
result of 103%, a very slight advantage regarding plasma
exposure in favour to the infusion group was observed.
It is worth pointing out that the missing urine data were not
because of urine wasting during collection phases. Urine losses
caused by technical reasons were insignificant relative to the
total volume. Moreover, the urine daily output was within
normal limits (5–15 L ⁄ day) (Tasker, 1966) for all horses of the
study. Therefore, the main limiting factor was the sensitivity of
the assay, particularly for group 1, where lower urine concen-
trations were measured. Another potential limitation in the
assessment of urinary tiludronate was the homogenization of
urine. Indeed, equine urine contains large amounts of calcium
crystals which may have adsorbed tiludronate. Particular
attention was paid to homogenization of the sediment during
urine sampling, but losses could have occurred. Whatever the
cause, the large number of missing data made urine excretion
values irrelevant, particularly in group 1. Despite this, the visual
inspection of the curves of cumulative urinary excretion suggests
that the arbitrary choice of continuous collection until 7 days
postlast administration was adequate to reach the plateau in all
horses. In both groups, most of the tiludronate had been excreted
by 24 h after the last administration (92.3% and 89.0% of the
total amount to be excreted in group 1 and 2, respectively), and
tiludronate was no longer quantifiable by 20 days post-treat-
ment in either group. Nevertheless, with a higher sensitivity of
the tiludronate assay in urine, the actual plateau of cumulative
excretion could have been reached later than it appeared in this
study. This would be consistent with the long residence time of
tiludronate in bone. This would also imply that the actual
terminal half-life in plasma could be longer than it appeared from
the plasma vs. time curves in the present study, and that a longer
sampling time along with a lower LOQ for the HPLC method used
for both plasma and urine would have been required.
To assess further the bioequivalence of the two dosage
regimens of tiludronate in horses, an evaluation of their
respective pharmacological effects was attempted. It was already
known that there was no difference in adverse effects between
these two dosage regimens (Varela et al., 2002). However, this is
the first time that the antiresorptive effects of the two dosages
had been examined. Objective assessment of the effects of
tiludronate in horses is challenging. For this purpose, different
techniques of bone imaging and density measurement have been
tested (Delguste et al., 2007). In human clinical trials, BMD and
biochemical markers of bone turnover are commonly used as
surrogate markers of the efficacy of bisphosphonates (i.e.
reduction of fracture risk) (Reid, 2006), although they have
not yet been validated for the management of individual
osteoporotic patients. In equine medicine, BMD can be measured
only in the cannon bone, which is generally not the target bone
of a tiludronate treatment. Blood CTX-1 is thought to be a
reliable marker of bone resorption in the equine species, and as
such is thought to be reflective of the general bone resorption
status of an individual (Kellerhouse et al., 2000; Billinghurst
et al., 2003; Camacho & Kleerekoper, 2006). As in humans,
large interindividual variations are observed in basal CTX-1
concentrations in horses; hence its evolution is commonly
expressed in percentage of baseline value (Kellerhouse et al.,
2000; Billinghurst et al., 2003; Delguste et al., 2007). Variations
can arise not only because of age, gender, breed or disease,
among others, but also because of circadian, hormonal or
alimentary reasons (Hannon & Eastell, 2000; Lepage et al.,
2001). Therefore, standardization of both horses’ characteristics
and sampling procedures are of paramount importance in the
design of a study evaluating biochemical markers of bone
turnover. Furthermore, in this study, lameness was evaluated
before inclusion in an attempt to exclude horses suffering from
significant bone pathologies susceptible to affect baseline value of
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CTX-1 significantly. Grade-1 lameness was considered as
unlikely to reflect significant bone disease, and was not an
exclusion criterion. Retrospectively, the two grade-1 lame
horses, which failed to present suggestive clues about the origin
of the lameness (horses 5 and 10), were the two horses with the
highest plasma CTX-1 baseline value of their respective group,
while the other three grade-1 lame horses of the study (horses 2,
3 and 11) had rather low baseline values. The subsequent
evolution of the plasma CTX-1 levels of horses 5 and 10
expressed as percentages of baseline value was similar to that of
the rest of their respective groups, although their levels remained
in the lowest range in the long term (from 30 and 10 days post-
treatment for horses 5 and 10, respectively). Therefore, it cannot
be ruled out that some degree of bone pathology had an impact
on CTX-1 results, and that the tiludronate treatment could have
inhibited an underlying process of enhanced bone resorption
during the whole study in these horses.
The sensitivity of blood CTX-1 makes it useful in the
monitoring of a tiludronate treatment in horses (Delguste et al.,
2007). In human medicine, serum and ⁄ or urine CTX-1 are PD
end-points commonly used in the efficacy evaluation of a
bisphosphonate treatment (Tanko et al., 2003; Nenonen et al.,
2005; Reginster et al., 2005; Cremers & Garnero, 2006; Ilter
et al., 2006; Peris et al., 2006; Lein et al., 2007). Correlations
have been found between the serum CTX-1 response to a
bisphosphonate therapy and reduction of fracture risk (Cremers
& Garnero, 2006). The overall evolution of CTX-1 observed in
this study showed no difference between groups, and in plasma,
a decrease in CTX-1 concentrations was observed in both groups
24 h after the first administration of tiludronate. While this
decrease was maximal 3 days after the infusion, the lowest
trough of the curve was reached 10 days after completion of
treatment in the bolus group. Nevertheless, no plasma CTX-1
assessment was performed between day 1 and day 5 in this
group, and a transient trough similar to the one observed in
group 2 on day 3 cannot be ruled out. Although at different
time-points, the maximal median inhibition of bone resorption
was similar in both groups, at around 70% of the baseline value.
For undetermined reasons, this CTX-1 decrease was less than
that in a previous study, where serum CTX-1 declined by 50%
after a 1 mg ⁄ kg tiludronate infusion (Delguste et al., 2007). In
this study, the interindividual variations were very large in the
bolus group in both plasma and urine, while evolution of CTX-1
seemed to present less variability in the infusion group. It was
therefore suspected that tiludronate administered in 10 lower
daily doses could have a less predictable effect on CTX-1 than a
single CRI of the total dose, or that some horses could be
nonresponders at the lower, repeated dosage. From the results of
CTX-1 in the infusion group, it seems that in horses, the
sensitivity of this marker is higher in plasma than in urine.
Moreover, urine collection can be challenging in horses, thus
favoring the assessment of blood rather than urine CTX-1 in
future studies. Therefore, urine CTX-1 results will not be further
discussed.
In human medicine, studies comparing different dosage
regimens of a same bisphosphonate have been reported (Tanko
et al., 2003; Reid, 2006). Indeed, less-frequent dosing is of great
interest as it can improve compliance with bisphosphonate
treatments. Such dosage regimen adaptations are based on the
concept that inhibition of bone resorption by a bisphosphonate is
determined by the total dose administered within a given period
(Tanko et al., 2003; Bauss & Russell, 2004). However, under
suboptimal dosing conditions, the overall efficacy of the antire-
sorptive treatment can also depend on the dynamics of loading
the skeletal system, i.e., frequency of dosing (Tanko et al., 2003;
Papapoulos & Schimmer, 2007).
This study suggests that the administration of a single dose of
1 mg ⁄ kg b.w. tiludronate as a CRI and daily i.v. administrations
as boluses of 0.1 mg ⁄ kg for 10 consecutive days, produce similar
plasma exposure and pharmacological effects in horses. Never-
theless, the response of the bone resorption marker CTX-1 to the
drug seemed to be less reproducible when the total dose of
1 mg ⁄ kg was administered as 10 daily doses than when it was
given as a single dose. The current multiple dose regimens could
be replaced by a single CRI in horses. Further clinical studies are
warranted to investigate efficacy of tiludronate on large cohorts
of horses suffering from bone diseases, and to confirm the interest
of CTX-1 as a biomarker useful in monitoring bisphosphonate
treatment in these horses.
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